V. Brichard, A. Van-pel, T. Wolfel, C. Wolfel, E. De-plaen et al., The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas, J. Exp. Med, vol.178, pp.489-495, 1993.

P. G. Coulie, V. Brichard, A. Van-pel, T. Wolfel, J. Schneider et al., A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas, J. Exp. Med, vol.180, pp.35-42, 1994.

A. L. Cox, J. Skipper, Y. Chen, R. A. Henderson, T. L. Darrow et al., Identification of a peptide recognized by five melanoma-specific human cytotoxic, T cell lines. Science, vol.264, pp.716-719, 1994.

S. Seiter, V. Monsurro, M. B. Nielsen, E. Wang, M. Provenzano et al., Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes, J. Immunother, vol.25, pp.252-263, 2002.

Y. Kawakami, N. Dang, X. Wang, J. Tupesis, P. F. Robbins et al., Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma, J. Immunother, vol.23, pp.17-27, 2000.

H. Benlalam, N. Labarriere, B. Linard, L. Derre, E. Diez et al., Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy, Eur. J. Immunol, vol.31, pp.2007-2015, 2001.
URL : https://hal.archives-ouvertes.fr/inserm-02482156

M. E. Dudley and S. A. Rosenberg, Adoptive-cell-transfer therapy for the treatment of patients with cancer, Nat. Rev. Cancer, vol.3, pp.666-675, 2003.

C. Yee, J. A. Thompson, D. Byrd, S. R. Riddell, P. Roche et al., Adoptive T cell therapy using antigen-specific CD8 ? T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells, Proc. Natl. Acad. Sci. USA, vol.99, pp.16168-16173, 2002.

N. Meidenbauer, J. Marienhagen, M. Laumer, S. Vogl, J. Heymann et al., Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients, J. Immunol, vol.170, pp.2161-2169, 2003.

C. Yee, J. A. Thompson, P. Roche, D. R. Byrd, P. P. Lee et al., Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo, J. Exp. Med, vol.192, pp.1637-1644, 2000.

M. Oelke, U. Moehrle, J. L. Chen, D. Behringer, V. Cerundolo et al., Generation and purification of CD8 ? melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy, Clin. Cancer Res, vol.6, 1997.

A. Van-elsas, S. H. Van-der-burg, C. E. Van-der-minne, M. Borghi, J. S. Mourer et al., Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen, Eur. J. Immunol, vol.26, pp.1683-1689, 1996.

N. Gervois, N. Labarriere, S. L. Guiner, M. C. Pandolfino, J. F. Fonteneau et al., High avidity melanomareactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells, Clin. Cancer Res, vol.6, pp.1459-1467, 2000.
URL : https://hal.archives-ouvertes.fr/inserm-02482162

N. Gervois, F. Heuze, E. Diez, and F. Jotereau, Selective expansion of a specific anti-tumor CD8 ? cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements, Eur. J. Immunol, vol.20, pp.825-831, 1990.

F. Jotereau, M. C. Pandolfino, D. Boudart, E. Diez, B. Dreno et al., High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy, J. Immunother, vol.10, pp.405-411, 1991.

T. Jung, U. Schauer, C. Heusser, C. Neumann, and C. Rieger, Detection of intracellular cytokines by flow cytometry, J. Immunol. Methods, vol.159, pp.197-207, 1993.

M. Bodinier, M. A. Peyrat, C. Tournay, F. Davodeau, F. Romagne et al., Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding, Nat. Med, vol.6, pp.707-710, 2000.

N. Labarriere, M. C. Pandolfino, N. Gervois, A. Khammari, M. H. Tessier et al., Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients, Cancer Immunol. Immunother, vol.51, pp.532-538, 2002.
URL : https://hal.archives-ouvertes.fr/inserm-02482115

A. Lim, V. Baron, L. Ferradini, M. Bonneville, P. Kourilsky et al., Combination of MHC-peptide multimer-based T cell sorting with the Immunoscope permits sensitive ex vivo quantitation and follow-up of human CD8 ? T cell immune responses, J. Immunol. Methods, vol.261, pp.177-194, 2002.

C. Pannetier, M. Cochet, S. Darche, A. Casrouge, M. Zoller et al., The sizes of the CDR3 hypervariable regions of the murine T-cell receptor ? chains vary as a function of the recombined germ-line segments, Proc. Natl. Acad. Sci. USA, vol.90, pp.4319-4323, 1993.

D. Valmori, J. F. Fonteneau, C. M. Lizana, N. Gervois, D. Lienard et al., Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues, J. Immunol, vol.160, pp.1750-1758, 1998.

D. Valmori, V. Dutoit, D. Lienard, D. Rimoldi, M. J. Pittet et al., Naturally occurring human lymphocyte antigen-A2 restricted CD8 ? T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients, Cancer Res, vol.60, pp.4499-4506, 2000.

M. Sensi, C. Traversari, M. Radrizzani, S. Salvi, C. Maccalli et al., Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1, Proc. Natl. Acad. Sci. USA, vol.92, pp.5674-5678, 1995.

S. Mantovani, B. Palermo, S. Garbelli, R. Campanelli, G. Della-cuna et al., Dominant TCR-? requirements for a self antigen recognition in humans, J. Immunol, vol.169, pp.6253-6260, 2002.

L. Trautmann, N. Labarriere, F. Jotereau, V. Karanikas, N. Gervois et al., Dominant TCR V ? usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigens, Eur. J. Immunol, vol.32, pp.3181-3190, 2002.

P. Y. Dietrich, F. A. Le-gal, V. Dutoit, M. J. Pittet, L. Trautman et al., Prevalent role of TCR ?-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen, J. Immunol, vol.170, pp.5103-5109, 2003.

S. Mandruzzato, E. Rossi, F. Bernardi, V. Tosello, B. Macino et al., Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient, J. Immunol, vol.169, pp.4017-4024, 2002.

P. Y. Dietrich, P. R. Walker, A. L. Quiquerez, G. Perrin, V. Dutoit et al., Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoires, Cancer Res, vol.61, pp.2047-2054, 2001.

F. Sallusto, D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia, Two subsets of memory T lymphocytes with distinct homing potentials and effector functions, Nature, vol.401, pp.708-712, 1999.

J. F. Fonteneau, E. Le-drean, S. L. Guiner, N. Gervois, E. Diez et al., Heterogeneity of biologic responses of melanoma-specific CTL, J. Immunol, vol.159, pp.2831-2839, 1997.

M. E. Dudley, J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu et al., Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes, Science, vol.298, pp.850-854, 2002.

P. F. Robbins, M. E. Dudley, J. Wunderlich, M. El-gamil, Y. F. Li et al., Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy, J. Immunol, vol.173, pp.7125-7130, 2004.

M. E. Dudley, J. Wunderlich, M. I. Nishimura, D. Yu, J. C. Yang et al., Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma, J. Immunother, vol.24, pp.363-373, 2001.

D. E. Speiser, M. J. Pittet, D. Valmori, R. Dunbar, D. Rimoldi et al., In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes, J. Exp. Med, vol.190, pp.775-782, 1999.

E. Le-drean, F. Vely, L. Olcese, A. Cambiaggi, S. Guia et al., Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases, Eur. J. Immunol, vol.28, pp.264-276, 1998.

A. Poggi, M. R. Zocchi, P. Costa, E. Ferrero, G. Borsellino et al., IL-12-mediated NKRP1A up-regulation and consequent enhancement of endothelial transmigration of V?2 ? TCR ?? ? T lymphocytes from healthy donors and multiple sclerosis patients, J. Immunol, vol.162, pp.4349-4354, 1999.

C. Lurquin, B. Lethe, E. De-plaen, V. Corbiere, I. Theate et al., Contrasting frequencies of antitumor and antivaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen, J. Exp. Med, vol.201, pp.249-257, 2005.

C. Germeau, W. Ma, F. Schiavetti, C. Lurquin, E. Henry et al., High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens, J. Exp. Med, vol.201, pp.241-248, 2005.